CLGN Stock Overview
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CollPlant Biotechnologies Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.13 |
52 Week High | US$8.90 |
52 Week Low | US$4.22 |
Beta | 0.34 |
1 Month Change | -19.72% |
3 Month Change | 2.40% |
1 Year Change | -31.96% |
3 Year Change | -73.49% |
5 Year Change | 2.60% |
Change since IPO | -72.22% |
Recent News & Updates
Recent updates
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Feb 03Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?
Nov 02CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business
Sep 06Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Jul 14Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Mar 02Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth
Nov 10CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M
Aug 25We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Jul 22CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 22CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
Aug 05Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation
Jul 29The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business
Jun 09Shareholder Returns
CLGN | US Biotechs | US Market | |
---|---|---|---|
7D | 0.002% | 0.2% | 1.2% |
1Y | -32.0% | 7.4% | 20.5% |
Return vs Industry: CLGN underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: CLGN underperformed the US Market which returned 20.5% over the past year.
Price Volatility
CLGN volatility | |
---|---|
CLGN Average Weekly Movement | 6.8% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CLGN's share price has been volatile over the past 3 months.
Volatility Over Time: CLGN's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 75 | Yehiel Tal | www.collplant.com |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.
CollPlant Biotechnologies Ltd. Fundamentals Summary
CLGN fundamental statistics | |
---|---|
Market cap | US$57.27m |
Earnings (TTM) | -US$7.50m |
Revenue (TTM) | US$10.62m |
5.5x
P/S Ratio-7.8x
P/E RatioIs CLGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLGN income statement (TTM) | |
---|---|
Revenue | US$10.62m |
Cost of Revenue | US$2.21m |
Gross Profit | US$8.41m |
Other Expenses | US$15.91m |
Earnings | -US$7.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.65 |
Gross Margin | 79.19% |
Net Profit Margin | -70.59% |
Debt/Equity Ratio | 0% |
How did CLGN perform over the long term?
See historical performance and comparison